Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting

Schedule of certain segment information

The following table includes certain segment information for the periods presented (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Grant and award revenue	$	1,159	$	2,973	$	3,819	$	3,939
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		190		1,858		(98)		5,459
AP-PA02: Cystic Fibrosis		-		-		25		235
AP-SA02: Bacteremia		404		1,618		2,067		2,752
AP-SA02: Prosthetic Joint Infection		-		-		2		8
Expenses not allocated by projects*		545		726		1,657		1,903
Total external research and development expenses		1,139		4,202		3,653		10,357
Research and development personnel expenses		2,287		2,874		6,893		8,296
Other research and development expenses		2,398		2,409		7,101		7,322
Total research and development expenses		5,824		9,485		17,647		25,975
General and administrative expenses:
General and administrative personnel expenses		1,141		1,273		3,733		3,778
Other general and administrative expenses		1,970		1,971		5,250		6,083
Total general and administrative expenses		3,111		3,244		8,983		9,861
Total operating expenses		8,935		12,729		26,630		35,836
Operating loss		(7,776)		(9,756)		(22,811)		(31,897)
Other income (expense), net		(18,899)		4,275		(26,690)		10,381
Net loss	$	(26,675)	$	(5,481)	$	(49,501)	$	(21,516)